Successful treatment by chemoradiotherapy for locally advanced cervical low-grade endometrial stromal sarcoma. Case report and review of the literature
Keywords:
low-grade endometrial stromal sarcoma, uterine cervix, treatmentAbstract
We describe the case of a 51-year-old patient with primary low-grade endometrial stromal sarcoma (ESS) of the uterine cervix (FIGO stage IIB). The patient was diagnosed with the neoplasm in June 2009. No synchronous extra-pelvic metastases were found. She was referred to chemoradiotherapy. Three cycles of AP-scheme (doxorubicin 60 mg/m2 and cisplatine 50 mg/m2; one cycle every 28 days) were administrated. External beam irradiation was divided into two steps. In the first step the uterus, both adnexa, parametria, and regional pelvic lymph nodes were irradiated (total dose of 39.6 Gy, 4 fields, 22 fractions of 1.8 Gy per fraction, 5 days/week). Afterwards, only the uterus and both adnexa were irradiated (total dose of 26.0 Gy, 3 fields, 13 fractions of 2.0 Gy per fraction, 5 days/week). As the last part of treatment, intracavitary brachytherapy was administered using a high-dose Ir192 source, with 7 Gy/2.0 cm being delivered to the vaginal surface in 1 fraction (intrauterine applicator 6 cm in diameter with vaginal cylinder 2.6 cm). Treatment was finished in January 2010. The patient, 57 months after the end of treatment, is still under control in our department. No signs of recurrence have been detected since then. We conclude that patients with primary low-grade ESS of the uterine cervix, even when locally advanced, can be successfully treated with combined chemoradiotherapy.
Downloads
Published
Issue
Section
License
OPEN ACCESS
All the articles of the European Journal of Oncology and Environmental Health are published with open access under the CC-BY Creative Commons attribution license (the current version is CC-BY, version 4.0 http://creativecommons.org/licenses/by/4.0/). This means that the author(s) retain copyright, but the content is free to download, distribute and adapt for commercial or non-commercial purposes, given appropriate attribution to the original article.
The articles in the previous edition of the Journal (European Journal of Oncology) are made available online with open access under the CC-BY Creative Commons attribution license (the current version is CC-BY, version 4.0 http://creativecommons.org/licenses/by/4.0/).
Upon submission, author(s) grant the Journal the license to publish their original unpublished work within one year, and the non exclusive right to display, store, copy and reuse the content. The CC-BY Creative Commons attribution license enables anyone to use the publication freely, given appropriate attribution to the author(s) and citing the Journal as the original publisher. The CC-BY Creative Commons attribution license does not apply to third-party materials that display a copyright notice to prohibit copying. Unless the third-party content is also subject to a CC-BY Creative Commons attribution license, or an equally permissive license, the author(s) must comply with any third-party copyright notices.